The Gut Microbiome in IVIg-Treated Chronic Inflammatory Demyelinating Polyneuropathy.
Martin K R SvačinaAlina Sprenger-SvačinaAnastasia TsakmaklisAlina M RübInes KleinHauke WüstenbergGereon R FinkMartin K R SvačinaMaria J G T VehreschildFedja FarowskiPublished in: European journal of neurology (2023)
The gut microbiome in IVIg-treated CIDP shows distinct features with increased bacterial diversity and enrichment of short-chain fatty acid (SCFA) producing Firmicutes. IVIg had no short-term impact on the gut microbiome in CIDP patients. As small cohort size is a main limitation of this exploratory pilot study, future studies also including therapy-naïve patients are warranted to verify our findings and to explore the impact of a long-term IVIg treatment on the gut microbiome in CIDP.